NEW YORK (GenomeWeb) – Chinese genetic testing firm Berry Genomics and Illumina have co-developed a next-generation sequencing system and are currently seeking approval for clinical applications from the Chinese Food and Drug Administration, the companies said today.

Under their partnership, the firms have developed a customized sequencer that is based on Illumina's NextSeq 500 and have integrated it with Berry's Bambni noninvasive prenatal test, which includes a PCR-free library prep kit and proprietary RUPATM analysis software.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: Icelandic genome sequences, approach to increase CRISPR efficiency, and more.

Testing showing "genetic incompatibilities" have led thousands of couples in Saudi Arabia to call off their weddings, the BBC reports.

Decode Genetics' ability to tell Icelanders, even ones the company hasn't sequenced, about their disease risk brings up ethical questions.

Genetic analysis of Britain's King Richard III and modern descendants of his relatives indicate breaks in the male line.